Phase 3

MAGNET trial

Platform trial

MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously. With this trial we will drastically increase the number of patients that can participate while minimizing patient burden and maximizing the chance to find effective treatments at the same time.

Multiple treatments at the same time

The MAGNET adaptive platform trial enables the investigation of multiple treatments at the same time. This allows for a rapid screening of new candidate treatments and will speed up the process of finding a cure for ALS. In addition, we can add new candidate drugs to the platform trial at any given time.

Lithium carbonate is the first promising candidate therapy to be studied using the MAGNET trial. This compound has already been shown to be safe in patients with ALS.

Learn more about how platform trials work

Lithium carbonate

Lithium carbonate has a long history as a treatment for mood disorders. Several studies have highlighted the protective effects of Lithium carbonate in the brain. An analysis of ALS patients treated with Lithium carbonate showed that patients carrying the homozygous UNC13a mutation may respond better than patients who do not carry this gene. The UNC13a gene is known to be associated with the prognosis and symptoms of patients with ALS.  Earlier studies have shown that lithium is safe for patients. In this treatment arm we aim to confirm the beneficial effect of Lithium carbonate in patients positive for the homozygous UNC13a mutation.

Read more about Lithium carbonate

Participant information

The MAGNET trial currently consists of one sub-study to test the efficacy of lithium carbonate. In the future we will add more sub-studies testing other candidate therapies. Each sub-study will have an active (i.e. real drug) and placebo arm (i.e. fake drug). Patients are randomly allocated in two-steps: first to sub-study and subsequently to active or placebo treatment.

This means that you cannot choose for a specific treatment or sub-study and the choice will be made for you at random. Both you and your physician do not know if you receive the active or the placebo treatment, but you will be aware to which sub-study you are allocated.

Criteria to participate

The criteria for participation in the MAGNET study are different than other clinical trials in ALS and aimed at providing more patients with the opportunity to participate. Instead of a list of stringent requirements, a computer model determines whether you are eligible to participate.

This computer model is based on your disease characteristics such as age, symptom duration and lung function. The computer makes a forecast of the expected disease pattern. By using this forecast, more than 75% of the patients will be able to participate instead of the 25 – 40% when using classical criteria.

In addition, patients that can participate:

  • Need to be 18 years or older
  • Cannot be pregnant or breastfeeding

You can still choose to continue your Riluzole treatment throughout the duration of the study.

Where can I register my interest?

The MAGNET Trial is currently in preparation. If you have been diagnosed with ALS and are interested in participating, you can register with the TRICALS registry.

Register as a patient

Sponsors

The innovative MAGNET trial would not be possible without financial support of these organisations

Other trials
Recruiting
Phase iii

ALXN1210-ALS-308 trial

Industry trial
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Read more
Recruiting
Phase iii

VALOR study

Industry trial
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
Read more
In preparation
Phase iii

The Lighthouse 2 trial

Investigator initiated trial
The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.
Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more